Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company is advancing a pipeline of "off-the-shelf" gamma delta T cells, which are engineered with chimeric antigen receptors (CARs) to provide durable activity in patients. Their manufacturing process for allogeneic gamma delta T cell product candidates uses peripheral blood cells from unrelated donors, allowing for rapid and cost-efficient generation of new product candidates. This "off-the-shelf" approach enables products from unrelated donors to be stored and sold on demand for patient treatment without causing a graft versus host immune response. This differs from alpha beta T cell products, which require individual patient manufacturing or extensive gene editing for unrelated donor cells. Adicet Bio's lead product candidate is prulacabtagene leucel (prula-cel, formerly ADI-001), a first-in-class allogeneic gamma delta T cell therapy that expresses a CAR targeting CD20. Prula-cel is being developed for the potential treatment of autoimmune diseases. In December 2023, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for prula-cel in lupus nephritis (LN). In August 2024, the prula-cel autoimmune clinical development program was expanded to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV). The company is also developing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA). ADI-212 is engineered with a novel CAR binder for enhanced tolerability and tumor-specific recognition, and integrates membrane-tethered IL-12 armoring and CRISPR/Cas9 mediated disruption of subunit 12 of the mediator complex (MED12) to enhance potency in solid tumors and deliver multiple anti-tumor mechanisms. Adicet Bio aims to submit a new regulatory submission, such as an IND application or equivalent, every 12-18 months.